Compare CRTO & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRTO | PTGX |
|---|---|---|
| Founded | 2005 | 2006 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 818.3M | 9.3B |
| IPO Year | 2013 | 2016 |
| Metric | CRTO | PTGX |
|---|---|---|
| Price | $16.30 | $142.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 13 |
| Target Price | $34.00 | ★ $108.23 |
| AVG Volume (30 Days) | 190.5K | ★ 526.9K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.95 | N/A |
| EPS | 0.37 | ★ 2.35 |
| Revenue | ★ $2,296,692,000.00 | N/A |
| Revenue This Year | N/A | $874.25 |
| Revenue Next Year | $5.54 | N/A |
| P/E Ratio | ★ $44.76 | $58.44 |
| Revenue Growth | ★ 27.65 | N/A |
| 52 Week Low | $15.58 | $62.24 |
| 52 Week High | $25.29 | $160.81 |
| Indicator | CRTO | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 33.95 | 46.76 |
| Support Level | $15.58 | $141.95 |
| Resistance Level | $19.85 | $151.24 |
| Average True Range (ATR) | 0.45 | 5.11 |
| MACD | -0.02 | -0.89 |
| Stochastic Oscillator | 4.70 | 48.37 |
Criteo SA is an ad-tech company in the digital advertising market. Its technology allows retailer advertisers to launch multichannel and cross-device marketing campaigns in real time. With real-time return on investment analysis of the ads, the firm's clients can adjust their marketing strategies dynamically. It has two reportable segments: Retail Media and Performance Media. Retail Media: This segment encompasses revenue generated from brands, agencies, and retailers for the purchase and sale of retail media digital advertising inventory and audiences, and services. Performance Media: This segment encompasses targeting capabilities and supply and AdTech services. The majority of its revenues is generated from the performance media segment.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.